Short Interest in 180 Life Sciences Corp. (NASDAQ:ATNF) Declines By 63.2%

180 Life Sciences Corp. (NASDAQ:ATNF) saw a large decline in short interest in January. As of January 31st, there was short interest totalling 52,200 shares, a decline of 63.2% from the January 15th total of 141,800 shares. Currently, 3.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 422,400 shares, the short-interest ratio is currently 0.1 days.

180 Life Sciences Trading Down 2.2 %

ATNF stock opened at $1.33 on Friday. 180 Life Sciences has a 1 year low of $1.16 and a 1 year high of $17.75. The company has a 50 day simple moving average of $1.71 and a 200 day simple moving average of $2.13.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of 180 Life Sciences in a research report on Saturday, February 1st.

Hedge Funds Weigh In On 180 Life Sciences

An institutional investor recently bought a new position in 180 Life Sciences stock. Rathbones Group PLC bought a new position in shares of 180 Life Sciences Corp. (NASDAQ:ATNF) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm bought 69,995 shares of the company’s stock, valued at approximately $127,000. Rathbones Group PLC owned 2.20% of 180 Life Sciences at the end of the most recent reporting period. Hedge funds and other institutional investors own 4.07% of the company’s stock.

About 180 Life Sciences

180 Life Sciences Corp., a clinical stage biotechnology company, focuses on developing therapeutics for unmet medical needs in chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company product development platforms includes fibrosis and anti-tumor necrosis factor (anti-TNF) platform, which has completed Phase IIb clinical trials that focuses on fibrosis and anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are synthetic pharmaceutical grade molecules close or distant analogs of non-psychoactive cannabinoids, such as CBD for the treatment of inflammatory diseases and pain; and a7nAChR platform, an immune suppressive, which is under preclinical trails that focuses on alpha 7 nicotinic acetylcholine receptor.